Karuna Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Meury
- Full Time Employees
- 339
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 99 High Street Boston MA United States of America 02110
- IPO Date
- Jun 28, 2019
- CIK
- 0001771917
- Website
- karunatx.com
- Similar Companies
- Business
- Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and delivering transformative medicines for people living with psychiatric and neurological conditions. The company's primary product is KarXT (xanomeline-trospium), an oral investigational muscarinic M1/M4-preferring agonist designed to treat schizophrenia and psychosis associated with Alzheimer's disease. KarXT is positioned as a potential first-in-class treatment, offering a novel mechanism of action distinct from existing dopaminergic and serotonergic pathway therapies. Karuna also develops a pipeline of early-stage and preclinical assets addressing neuropsychiatric disorders. The company operates primarily in the United States and was founded in 2016, headquartered in Boston, Massachusetts. In a major corporate development, Karuna Therapeutics was acquired by Bristol Myers Squibb in March 2024 for approximately $14 billion, becoming a wholly owned subsidiary. This acquisition significantly expanded Bristol Myers Squibb's neuroscience portfolio, centering on KarXT, which received FDA acceptance for its new drug application with a Prescription Drug User Fee Act (PDUFA) target date of September 26, 2024, positioning it for potential market approval as the first new treatment for schizophrenia in decades. Post-acquisition, Bristol Myers Squibb has taken steps to commercialize KarXT under the brand name Cobenfy, which reported initial sales since launch. Additionally, Karuna initiated the ADEPT-3 open label extension trial focusing on Alzheimer’s disease psychosis and continues development on its early-stage programs, reinforcing its commitment to neuropsychiatric conditions. The acquisition and product launches represent significant strategic shifts consolidating Karuna's novel therapeutic assets within a global pharma leader's pipeline for broader market reach and late-stage development acceleration. Karuna Therapeutics operates within the biotechnology industry segment specializing in CNS disorders, targeting patient populations with serious mental illnesses including schizophrenia and Alzheimer’s disease psychosis. Its acquisition by Bristol Myers Squibb aligns with broader pharma trends to innovate in neuroscience therapeutics amid significant unmet medical needs in psychiatric care. The company was founded in 2016 and is headquartered in Boston, Massachusetts. Its integration into Bristol Myers Squibb's global operations furthers its geographic reach and development capabilities, focusing on U.S. and global markets for neuropsychiatric therapy commercialization. Recent corporate changes include the cessation of Karuna’s independent public trading upon acquisition and ongoing clinical trial expansions under the new ownership. This description covers Karuna’s core product portfolio with a focus on KarXT and its developmental status, the recent major change of acquisition by Bristol Myers Squibb, and its position within the psychiatric and neurological treatment market. It reflects the latest corporate and product developments as of late 2025.
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
Bullish Continuation in '24? 3 Market Areas to Watch
Cramer names biopharma companies to watch as industry mergers start to pile up
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
Yes Virginia, There Is a Santa Claus Rally
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
Biotech stocks set for a rebound in 2024, analysts say
Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
A Major Acquisition and Other News Ahead of the Holiday Weekend
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
Bristol Myers to buy Karuna Therapeutics for $14B